The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft modelsSarah V. Holt, Paul D. Smith, Armelle Logié et al.|British Journal of Cancer|2012Cited by 111
Antitumor activity of the WEE1 inhibitor AZD1775 as a monotherapy and in combination with the PARP inhibitor olaparib in patient-derived explant (PDX) modelsM.J. O’Connor, J.F. Liu, Zhongwu Lai et al.|European Journal of Cancer|2016Cited by 3
497 Combination therapy with an Aurora B kinase inhibitor AZD1152 and AraC, shows enhanced tumouricidal activity in a preclinical model of acute myeloid leukaemia (AML)Robert W. Wilkinson, Emma L. Anderson, Rajesh Odedra et al.|European Journal of Cancer Supplements|2010Cited by 0